icon
icon

About Us

Success Stories

Careers

Quick Links

Contact

Media

Centre for Cancer Immunotherapy [CCI]

Mission

The Centre for Cancer Immunotherapy [CCI] mission is to improve cancer patient outcomes by advancing translation cancer research, development and application of cancer immunology and immunotherapy.

Our goal is to undertake “Bench to Bedside” discoveries & innovations involving process of translating scientific discoveries from laboratory to clinical practice to save more lives, help cancer patients live longer, healthier lives with the optimal patient care.

MGH
MGH

About

The Centre for Cancer Immunotherapy [CCI] is at the forefront of exploring new avenues for novel immune-based cancer treatments, as well as predicting and improving the effectiveness of existing immunotherapies.

Our findings have opened up new avenues for bench-to-bedside translation and have contributed toward the development of novel Dendritic Cell-based immunotherapeutic approach that is autologous, affordable, personalized and with no side effects cancer immunotherapy for better cancer treatment and management.

Manufacturing Facility for Dendritic cell-based vaccine

CCI has the first state-of-art platform Manufacturing facility Clean Room1000 particle free [ISO-6] in Northern India for cancer immunotherapy. In addition, we are well equipped in our Ancillary platform of CCI for carrying out experimental studies and providing necessary support to the primary activities & operation of a 1000 particle free rooms for Dendritic Cell- based vaccine production. Our goal is to accelerate and synergize efforts to quickly translate fundamentals from basic cancer research into the clinics for effective treatment of cancer patients.

Drug Controller General of India (DCGI), Central Drug Standard, Control Organization (CDSCO), New Delhi, Central Licensing Authority of India & State Licensing Authority (SLA), Drug Controller of Rajasthan has approved our Manufacturing facility and granted permission and licence for Manufacturing of Active Pharmaceutical Dendritic Cell based vaccine production for Breast cancer & Gallbladder cancer

Manufacturing Facility

  • Have ISO grade cleanrooms with controlled environmental conditions to minimize contamination risks and to adhere to the most stringent quality standards with specific requirements ensuring all environmental parameters are controlled and monitored.
  • Wall panels are extremely critical for Cleanrooms. Our wall panels are made up of Glass Reinforced Polyester (GRP) panel system.
  • Cleanroom is with dedicated air handling unit (AHU) for HEPA filtration systems to maintain air cleanliness levels for the ISO6 dendritic cell vaccine manufacturing facility.
  • Clean room AHU is having back-up of uninterruptible power supply (UPS) to prevent devices and systems from power supply problems, such as a power failure.
  • Cleanroom doors have interlock system to prevent both doors from being opened at some time. This is to prevent particulates from directly entering the cleanroom from outside the clean room. Door interlock system components are door open sensor, door magnetic lock, PLC control and emergency release button. It also has a buzzer that goes off when a door is open. There is a timer to delay second door opening to give airlock time to flush particles.
  • The emergency release button is for use when somebody is trapped in airlock and must exit for safety reasons. It overrides the interlock system to allow the second door to be opened even if the first door is not closed.
  • In order to control personnel moment in manufacturing area, and to ascertain whether they are authorized and qualified to operate in the area we have provided Biometric access control (card- based door opening) to specific staff who will be taking care of maintenance and will be working on manufacture process of drug respecting GMP standards.

Permission and License Granted by DCGI, Central Licensing Authority, New Delhi & State Licensing Authority, Drug Controller, Rajasthan

Breast cancer

Permission to manufacture new drug or investigational new drug for examination, test, and analysis: Dendritic cell vaccine; Indication- Recurrent/metastatic triple negative breast cancer (TNBC) DCG(I) Permission Number: SW/BIO-SC/CT-11/2024/000001; Dated 27th September 2024 Indication Breast cancer

Gallbladder cancer

Permission to manufacture new drug or investigational new drug for examination, test, and analysis: Dendritic cell vaccine; Indication- Non-resectable, locally advanced/metastatic gallbladder cancer DCG(I) Permission Number: SW/BIO-SC/CT-11/2024/000002: Dated 27th September 2024 Indication Gallbladder cancer

Translational Cancer Research Programs

CCI is in continuous process to develop and standardize methodologies for measuring the immune response to these investigational immunotherapies and establishing new tumor markers for clinical response. Oral Cavity Cancer (OCC), Gallbladder Cancer, Triple negative breast cancer biomarker investigations are ongoing for better diagnosis. In addition, CCI focus is also driven toward exploring the involvement Tumor microenvironment (TME), Molecular Mechanism of Cancer, Gene Regulation in Cancer (GRC), Cell Cycle and Tumorigenesis in order to understand various aspects of clinical relevance that would help medical oncologists with the course of treatment available for various cancers for better prognosis and will have a huge impact on the outcome of cancer treatment.

Our Leadership

Anil K. Suri
Prof. (Dr.) Anil K. Suri, FNASc, FAMS

Director, Centre for Cancer Immunotherapy (CCI)

Excellent track record of achievements, therapeutic cancer vaccine, innovations and Translation cancer research of clinical relevance- Bench to Bedside to improve human health.

Former Director, National Institute of Immunology, New Delhi, India Faculty & Visiting Professor: Memorial Sloan-Kettering Cancer Centre, Mount Sinai Medical Centre, Weill Cornell Medical College, National Cancer Institute (NCI), Lombardi Comprehensive Cancer Centre, Georgetown University Medical Centre, Medical Health Services, University of Virginia, University of Washington, USA Queen’s University Belfast, UK, Hyogo College of Medicine, Japan

Nirmala Jagadish
Prof. (Dr.) Nirmala Jagadish

Deputy Director, Centre for Cancer Immunotherapy (CCI)

Excellent track record of achievements, Biomarker discovery platform, therapeutic cancer vaccine, Translation cancer research of clinical relevance- Bench to Bedside to improve human health.

Scientist and Visiting Faculty: Memorial Sloan-Kettering Cancer Centre, Irving Medical Centre, Columbia Medical College, National Institute of Immunology

Ancillary Facility providing necessary support for operation of Manufacturing Facility for Dendritic Cell- based vaccine production.

MGH

Manufacturing Facility for Dendritic Cell- based vaccine production

  • Cyberknife
  • Cyberknife
  • Cyberknife
  • Cyberknife
Book an Appointment Book an Appointment
Specialities Specialities
Patient Support Patient Support
Menu Menu

Book an Appointment

arrow arrow
  • icon

    18001806002

  • icon

    guestrelations@mgumst.org

  • icon

    RIICO Institutional Area, Sitapura, Tonk Road, Jaipur - 302 022 (Rajasthan) INDIA

    • International Patient
    Test & Health Packages
    Contact Us